Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00146328 · ClinicalTrials.gov registry record · Phase 2
Rollover Trial Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV 1 Infected Subjects
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 2
- Development phase
- 997
- Enrollment target
NCT00146328 is a Phase 2 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 997 participants.
The verdict
NCT00146328, a Phase 2 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 997 participants
- Enrollment target
Study Summary
The objective of this study is to determine the long term safety and tolerability of multiple oral doses of tipranavir (Aptivus) and ritonavir with a focus on the long term safety of the development dose (500 mg tipranavir/200 mg ritonavir BID) when administered with other antiretroviral medications.
Interventions
- DRUG Tipranavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 997 participants |
| Start Date | 2001-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00146328
The ClinicalTrials.gov registry entry for NCT00146328 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 997 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tipranavir is the first listed.
NCT00146328 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00146328 about?
NCT00146328 is a clinical study titled "Rollover Trial Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV 1 Infected Subjects". The objective of this study is to determine the long term safety and tolerability of multiple oral doses of tipranavir (Aptivus) and ritonavir with a focus on the long term safety of the development dose (500 mg tipranavir/200 mg ritonavir BID) when administered with other antiretroviral medications...
What is the current status of trial NCT00146328?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 997 participants. The study started on 2001-04.
What interventions are being tested in trial NCT00146328?
The interventions under investigation include: Tipranavir (DRUG).
Who is sponsoring clinical trial NCT00146328?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.